Critical Appraisal of Bivalirudin versus Heparin for Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials

Anthony A. Bavry1,2*, Islam Y. Elgendy2, Ahmed Mahmoud2, Manoj P. Jadhav2, Tianyao Huo2

1 North Florida/South Georgia Veterans Health System, Gainesville, Florida, United States of America, 2 Department of Medicine, University of Florida, Gainesville, Florida, United States of America

* anthony.bavry@va.gov

Abstract

Percutaneous coronary intervention with bivalirudin plus bail-out glycoprotein IIb/IIIa inhibitors has been shown to be as effective as unfractionated heparin plus routine glycoprotein IIb/IIIa inhibitors in preventing cardiac ischemic events, but with a lower bleeding risk. It is unknown whether bivalirudin would have the same beneficial effects if compared with heparin when the use of glycoprotein IIb/IIIa inhibitors was similar between treatment arms. We searched the MEDLINE, Web of Science, and Cochrane databases from inception until March 2015 for randomized trials that compared bivalirudin to heparin in patients undergoing percutaneous coronary intervention. We required that the intended use of glycoprotein IIb/IIIa inhibitors was similar between the study groups. Summary estimates were principally constructed by the Peto method. Fifteen trials met our inclusion criteria, which yielded 25,824 patients. Bivalirudin versus heparin was associated with an increased hazard of stent thrombosis (odds ratio [OR] 1.49, 95% confidence interval [CI] 1.15-1.92, \( P = .002, I^2 = 16.9\% \)), with a similar hazard of myocardial infarction (OR 1.09, 95% CI 0.98-1.22, \( P = .11, I^2 = 35.8\% \)), all-cause mortality (OR 0.88, 95% CI 0.72-1.08, \( P = .21, I^2 = 31.5\% \)) and major adverse cardiac events (OR 1.04, 95% CI 0.94-1.14, \( P = .46, I^2 = 53.9\% \)). Bivalirudin was associated with a reduced hazard of major bleeding (OR 0.80, 95% CI 0.70-0.92, \( P = .001, I^2 = 63.5\% \)). The dose of heparin in the control arm modified this association; when the dose of unfractionated heparin in the control arm was \( > 100 \) units/kg, bivalirudin was associated with a reduction in major bleeding (OR 0.55, 95% CI 0.45-0.68, \( P < .0001 \)), but when the dose of unfractionated heparin was \( \leq 75 \) units/kg, bivalirudin was not associated with a reduction in bleeding (OR 1.09, 95% CI 0.91-1.31, \( P = .36 \)). Among patients undergoing PCI, bivalirudin was associated with an increased hazard of stent thrombosis. Bivalirudin may be associated with a reduced hazard of major bleeding; however, this benefit was no longer apparent when compared with a dose of unfractionated heparin \( \leq 75 \) units/kg.
Introduction

Unfractionated heparin has been widely used for anticoagulation during percutaneous coronary intervention (PCI). The addition of glycoprotein IIb/IIIa inhibitors to unfractionated heparin has been shown to reduce peri-procedural ischemic events compared with heparin alone; however, this approach can increase bleeding risk [1].

The Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial demonstrated that bivalirudin, a direct thrombin inhibitor, was non-inferior to unfractionated heparin combined with a routine glycoprotein IIb/IIIa inhibitor in preventing major adverse cardiac events (MACE), but with a lower risk of bleeding [2]. Both unfractionated heparin and bivalirudin are approved by the European Medicines Agency and United States Food and Drug Administration and endorsed by the European Society of Cardiology and American College of Cardiology/American Heart Association as acceptable anticoagulants during PCI [3,4].

A recent meta-analysis compared a bivalirudin-based regimen with a heparin-based regimen during PCI [5]. The study concluded that bivalirudin increased the risk of MACE, myocardial infarction, and stent thrombosis. There was significant heterogeneity in major bleeding and bivalirudin was only associated with a reduction in major bleeding when compared with heparin plus a routine glycoprotein IIb/IIIa inhibitor. This is not a novel finding since the reduction in major bleeding with bivalirudin has been consistently observed in analyses in which the control arm routinely used glycoprotein IIb/IIIa inhibitors in addition to heparin [6]. As the routine use of glycoprotein IIb/IIIa inhibitors during PCI is no longer contemporary, and may confound any associations between bivalirudin and ischemic/bleeding events, we aimed to conduct a comprehensive meta-analysis to compare the efficacy and safety of bivalirudin versus heparin during PCI, while controlling for the use of glycoprotein IIb/IIIa inhibitors.

Materials and Methods

Data Sources

We performed a computerized literature search of the MEDLINE database without language restriction from inception until March 2015 using the search strategy shown in Fig 1[2,7–43]. We also searched both the Web of Science and Cochrane databases using the keywords “bivalirudin” and “heparin”, which did not identify additional studies beyond MEDLINE. Additionally, we searched for abstracts of scientific sessions reported in European Heart Journal, Circulation, and Journal of the American College of Cardiology from 2012 onwards using the same keywords. To ensure that no potentially important studies were missed, the reference lists from the retrieved articles and prior meta-analyses were also checked.

Selection Criteria

We selected studies that reported clinical outcomes at 30 days (or during hospitalization if 30-day outcomes were not available) in which patients were randomized to receive either bivalirudin or heparin during PCI. We required that patients were randomized to 1) bivalirudin plus a bail-out glycoprotein IIb/IIIa inhibitor versus heparin plus a bail-out glycoprotein IIb/IIIa inhibitor or 2) bivalirudin plus a routine glycoprotein IIb/IIIa inhibitor versus heparin plus a routine glycoprotein IIb/IIIa inhibitor. Bivalirudin was given as a bolus (0.75 mg/kg), followed by infusion (1.75 mg/kg/hour for the duration of the procedure). Heparin could be administered as either unfractionated or low-molecular-weight heparin. The dose of unfractionated heparin ranged from 60 to 140 units/kg. We excluded studies that randomized patients to bivalirudin plus a bail-out glycoprotein IIb/IIIa inhibitor versus heparin plus a
routine glycoprotein IIb/IIIa inhibitor, and studies that used different adenosine diphosphate (ADP) receptor antagonists between treatment arms. Additionally, in order to focus on contemporary practice, we excluded trials that did not routinely use stents.

Data Extraction

Two authors (IYE and AM) independently extracted data on study design, sample size, and other study characteristics from the included randomized-controlled trials using a standardized form. A third author (MPJ) verified the data. Any discrepancies were resolved by consensus of the authors. When necessary for data or article clarification, personal communication was made with select study authors. For all clinical outcomes, we tabulated the number of events that occurred for each outcome of interest in each arm of each trial.

Outcomes and Definitions

The efficacy outcomes that were tested were stent thrombosis, MACE, all-cause mortality, non-fatal myocardial infarction (MI), and revascularization, while major bleeding, minor bleeding, and net adverse clinical outcomes (NACE) were assessed as safety outcomes.

MACE and NACE were variably defined according to the individual trials (S1 Table) [29–43]. We defined stent thrombosis as definite or probable according to the Academic Research Consortium [44]. Revascularization was defined as urgent, unplanned, or ischemia-driven. MI was defined either as a peri-procedural rise in cardiac biomarkers > 3 times the 99th percentile of the upper reference limit or the combination of ischemic symptoms and/or electrocardiographic changes suggestive of ischemia along with a 3-fold increase in the pre-procedural biomarker level. Most of the trials used the REPLACE-2 criteria for major bleeding (ie, intracranial, intra-ocular, or retroperitoneal hemorrhage, clinically overt blood loss resulting in a decrease in hemoglobin of more than 3 g/dl, any decrease in hemoglobin of more than 4 g/dl, or transfusion of two or more units of packed red cells or whole blood) [2].

---

**Fig 1. Study selection flow diagram.** Summary of how the systematic search was conducted and eligible studies were identified. ACC = American College of Cardiology; ADP = adenosine diphosphate; AHA = American Heart Association; ESC = European Society of Cardiology; GP IIb/IIIa = glycoprotein IIb/IIIa; MeSH = Medical Subject Headings; TCT = Transcatheter Cardiovascular Therapeutics.

doi:10.1371/journal.pone.0127832.g001
Statistical Analysis

We analyzed outcomes by the intention-to-treat analysis. Summary estimates were principally constructed by a fixed-effect model. We used the Peto method for construction of a fixed-effect summary odds ratio (OR) [45,46]. Additionally, we conducted a Shuster, Guo, and Skyler analysis, which is a random effects method for low—event-rate binomial data [47]. The Cochrane Handbook advises against using inverse variance random effects methods such as DerSimonian-Laird for low—event-rate data [45]. To quantify the statistical heterogeneity for each outcome of interest, we used the I² statistic. I² statistic values < 25%, 25% to 50%, > 50% were considered as low, moderate, and high degree of heterogeneity, respectively [48]. We assessed the risk for publication bias using Harbord’s method [49]. We conducted this analysis according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines [50]. Furthermore, we assessed the quality of the trials based on the adequate description of treatment allocation, blinded outcome assessment, and description of losses to follow-up [51]. All p-values were 2-tailed, with statistical significance set at 0.05, and confidence intervals (CIs) were calculated at the 95% level for the overall estimates effect. All analyses were performed using STATA software version 11 (STATA Corporation; College Station, Texas) or SAS 9.3 (SAS Institute Inc.; Cary, North Carolina) according to the applicable method.

Additional Analyses

In addition to the primary analysis that involved all of the retrieved trials that compared bivalirudin to heparin, we conducted a sensitivity analysis that excluded 1) trials that allowed for upstream use of non-study anticoagulation prior to randomization, and 2) trials that had a modest difference in glycoprotein IIb/IIIa inhibitor use between treatment arms. We also conducted subgroup analyses to explore for possible effect modification: 1) acute coronary syndrome versus elective cases on stent thrombosis and major bleeding, 2) unfractionated heparin (≤ 75 units/kg) versus unfractionated heparin (≥ 100 units/kg) on major bleeding, and 3) majority radial versus majority femoral procedures on major bleeding.

Results

Baseline Characteristics

Overall, we identified 15 studies with 25,824 patients available for analysis: 13,255 in the bivalirudin arm and 12,569 in the heparin arm [29–43]. For ACUITY we used the pre-specified cohort of patients that underwent PCI [42], and for EUROMAX we used the bivalirudin arm and the pre-specified cohort of patients that received heparin plus a bail-out glycoprotein IIb/IIIa inhibitor [34]. For the MATRIX trial, glycoprotein IIb/IIIa inhibitor use (i.e., routine or bail-out) was left to operator discretion; however, the majority of patients in the control arm received heparin (100 units/kg) plus a bail-out glycoprotein [29]. The dose of bivalirudin used during the procedure was similar in all of the studies, except for one study in which the bivalirudin dose was 0.1 mg/kg bolus followed by 0.25mg/kg/hour, with an additional 0.5 mg/kg bolus prior to PCI and the infusion increased to 1.75 mg/kg/hour for the duration of the procedure [42]. In EUROMAX, the protocol specified that bivalirudin be continued for at least 4 hours at a dose of 0.25 mg/kg/hour [34]. In MATRIX, 48% underwent a prolonged infusion of bivalirudin after PCI [29]. The mean duration of follow-up was 28.5 days. The mean age was 64 years in the bivalirudin group versus 65 years in the heparin group. The baseline characteristics and follow-up duration are summarized in Table 1. Table 2 reports the medications used in the trials. S2 Table provides measures of study quality [29–43].
Stent Thrombosis

The incidence of stent thrombosis was 1.2% in the bivalirudin arm versus 0.8% in the heparin arm (OR 1.49, 95% CI 1.15–1.92, P = .002, I² = 16.9%) with no evidence of publication bias with Harbord’s test (P = .57). This association remained the same in a sensitivity analysis that excluded trials that allowed for upstream use of anticoagulation (MATRIX, SWITCH III, ACUITY-PCI [29,36,42]) (OR 1.96, 95% CI 1.28–3.00, P = .002) and in a sensitivity analysis that excluded trials with a modest difference in glycoprotein IIb/IIIa inhibitor usage between study arms (MATRIX, EUROMAX, SWITCH III, ARNO [29,34,36,38]) (OR 1.50, 95% CI 1.07–2.11, P = .018). Bivalirudin versus heparin was associated with an increased hazard of acute stent thrombosis (within 24 hours) (OR 2.00, 95% CI 1.23–3.23, P = .005), but not with

Table 1. Baseline Characteristics and Follow-up Duration.

| Trial (ref#)                                                                 | Year | Patients, n | Age, mean (SD) | Men, % | DM, % | Prior MI, % | Radial access, % | Follow-up duration | ACT target value, sec | Indication for PCI               |
|------------------------------------------------------------------------------|------|-------------|----------------|--------|-------|-------------|------------------|---------------------|------------------------|--------------------------------|
| Bivalirudin plus a bail-out glycoprotein IIb/IIIa inhibitor versus heparin plus a bail-out glycoprotein IIb/IIIa inhibitor: |      |             |                |        |       |             |                  |                     |                        |                                |
| MATRIX [29]                                                                 | 2015 | 3,610/3,603 | 65(12)/65      | 76/77 |       |             | 50/50            | 30-days            | NR                     | STEMI/NSTEMI               |
| BRIGHT [30]                                                                 | 2015 | 735/729     | 57(12)/58      | 83/82 |       |             | 4.4/4.5          | 78/79              | 30-days               | 250–300* STEMI/NSTEMI       |
| NAPLES III [31]                                                             | 2015 | 418/419     | 78(4)/78(4)    | 50/56 |       |             | 42/38            | 0.5/0.5            | In-hospital            | 250 Elective               |
| ACRIPAB [32]                                                                | 2014 | 50/50       | 68(11)/65      | 78/60 |       |             | 40/34            | 90/78              | In-hospital            | 250 Elective and some ACS†  |
| HEAT-PPCI [33]                                                              | 2014 | 905/907     | 63(NR)/64      | 72/73 | 13/15 |             | 14/10            | 80/82              | 28-days               | 200 STEMI                  |
| EUROMAX [34]                                                                | 2014 | 1,089/460   | 61(NR)/62      | 75/77 |       |             | 7/10             | 48/41              | 30-days               | None STEMI                |
| Xiang et al. [35]                                                           | 2013 | 110/108     | 57(6)/59(5)    | 92/89 |       |             | 42/42            | 24/27              | 30-days               | 225 Elective              |
| SWITCH III [36]                                                             | 2012 | 51/49       | 63(12)/62      | 73/63 | 14/20 |             | NR               | 69/67              | 200* Urgent for ACS      |
| ARMYDA-7 BIVALVE [37]                                                       | 2012 | 198/203     | 70(8)/70       | 71/72 |       |             | 37/34            | 2/2                 | 30-days               | NR Elective‡               |
| ARNO [38]                                                                   | 2010 | 425/425     | 69(11)/69      | 77/75 |       |             | 41/38            | 2/2                 | 30-days               | 250–300* Elective          |
| ISAR-REACT 3 [39]                                                           | 2008 | 2,289/2,281 | 67(10)/67      | 76/77 |       |             | 32/30            | 0/0                 | 30-days               | None Elective             |
| Bivalirudin plus a routine glycoprotein IIb/IIIa inhibitors versus heparin plus a routine glycoprotein IIb/IIIa inhibitors: |      |             |                |        |       |             |                  |                     |                        |                                |
| Desphande et al. [40]                                                      | 2012 | 49/52       | 55(10)/57      | 90/85 |       |             | 25/35            | 30-days            | 200–250* Elective§      |
| TENACITY [41]                                                               | 2011 | 185/198     | NR             | NR    | NR    |             | NR               | 30-days            | 225 Mainly urgent for ACS |
| ACUITY-PCI [42]                                                             | 2007 | 2,609/2,561 | 62(NR)/63      | 74/73 |       |             | 30/30            | 30-days            | 200–250* Urgent for ACS  |
| REPLACE-1 [43]                                                              | 2004 | 532/524     | 64(12)/64      | 69/71 |       |             | 39/45            | 3/3                 | In-hospital            | 200–300* Elective          |

* ACT was checked only in the heparin arm
† 32% of patients had non-ST-elevation myocardial infarction
‡ Elective in patients with high bleeding risk
§ Elective in patients with high ischemic risk

Data are formatted as bivalirudin arm/ heparin arm

ACS = acute coronary syndrome; ACT = activated clotting time; DM = diabetes mellitus; MI = myocardial infarction; NSTEMI = Non-ST-elevation myocardial infarction; NR = not reported; PCI = percutaneous coronary intervention; SD = standard deviation; STEMI = ST-elevation myocardial infarction.

doi:10.1371/journal.pone.0127832.t001

Stent Thrombosis

The incidence of stent thrombosis was 1.2% in the bivalirudin arm versus 0.8% in the heparin arm (OR 1.49, 95% CI 1.15–1.92, P = .002, I² = 16.9%) with no evidence of publication bias with Harbord’s test (P = .57). This association remained the same in a sensitivity analysis that excluded trials that allowed for upstream use of anticoagulation (MATRIX, SWITCH III, ACUITY-PCI [29,36,42]) (OR 1.96, 95% CI 1.28–3.00, P = .002) and in a sensitivity analysis that excluded trials with a modest difference in glycoprotein IIb/IIIa inhibitor usage between study arms (MATRIX, EUROMAX, SWITCH III, ARNO [29,34,36,38]) (OR 1.50, 95% CI 1.07–2.11, P = .018). Bivalirudin versus heparin was associated with an increased hazard of acute stent thrombosis (within 24 hours) (OR 2.00, 95% CI 1.23–3.23, P = .005), but not with
sub-acute stent thrombosis (> 24 hours) (OR 1.07, 95% CI 0.63–1.81, \( P = .80 \)). The excess hazard of stent thrombosis with bivalirudin versus heparin was observed in acute coronary syndrome trials (OR 1.50, 95% CI 1.14–1.97, \( P = .004 \)), but not in elective trials (OR 1.41, 95% CI 0.68–2.93, \( P = .35 \)) (Fig 2).

**Major Bleeding**

The incidence of major bleeding was 3.1% in the bivalirudin arm versus 3.8% in the heparin arm (OR 0.80, 95% CI 0.70–0.92, \( P = .001 \), \( I^2 = 63.5\% \)), with no evidence of publication bias with Harbord’s test (\( P = .36 \)). This association remained the same in a sensitivity analysis that excluded trials that allowed for upstream use of anticoagulation (MATRIX, SWITCH III,
ACUITY-PCI [29,36,42]) (OR 0.66, 95% CI 0.54–0.81, P < .0001), but not in a sensitivity analysis that excluded trials with a modest difference in glycoprotein IIb/IIIa inhibitor usage between study arms (MATRIX, EUROMAX, SWITCH III, ARNO [29,34,36,38]) (OR 0.93, 95% CI 0.80–1.08, P = .35). The reduced hazard of major bleeding with bivalirudin versus heparin was observed in 1) elective trials (OR 0.69, 95% CI 0.54–0.89, P = .005), and in acute coronary syndrome trials (OR 0.85, 95% CI 0.72–0.99, P = .04); 2) unfractionated heparin ≥100 units/kg (OR 0.55, 95% CI 0.45–0.68, P < .0001), but not with unfractionated heparin ≤75 (OR 1.09, 95% CI 0.91–1.31, P = .36) (Fig 3); and 3) majority femoral procedures (OR 0.69, 95% CI 0.53–0.89, P = .004), and with majority radial procedures (OR 0.61, 95% CI 0.48–0.78, P < .0001).

Other Outcomes

Bivalirudin versus heparin was associated with similar hazard of myocardial infarction (OR 1.09, 95% CI 0.98–1.12, P = .11, I² = 35.8%), all-cause mortality (OR 0.88, 95% CI 0.72–1.08, P = .21, I² = 31.5%), revascularization (OR 1.23, 95% CI 0.98–1.55, P = .077, I² = 27.8%), MACE (OR 1.04, 95% CI 0.94–1.14, P = .46, I² = 53.9%), minor bleeding (OR 0.99, 95% CI 0.89–1.10, P = .81, I² = 60.6%), and a decreased hazard of net adverse cardiac events (OR 0.91, 95% CI 0.84–0.99, P = .028, I² = 67.4%). Outcomes are reported in Table 3.

Discussion

Among a broad spectrum of patients undergoing PCI, the use of bivalirudin was associated with a 49% increased hazard for stent thrombosis when compared with heparin. This was due to an increase in acute stent thrombosis. Risk was apparent in acute coronary syndrome trials, but did not achieve significance in elective trials. Stent thrombosis was the most robust finding in this analysis. There was no evidence for publication bias and very little heterogeneity of treatment effect for this outcome. The hazard for stent thrombosis was significantly increased using both the Peto method that is generally favored for outcomes with low event rates [46].
and the Shuster, Guo, and Skyler method which was specifically designed for low—event-rate binomial outcomes [47].

The association between bivalirudin and major bleeding was less conclusive. Bivalirudin was associated with a reduction in major bleeding with the Peto method, but not the Shuster, Guo, and Skyler method. This association was no longer significant in a sensitivity analysis that excluded trials with a modest difference in glycoprotein IIb/IIIa inhibitor usage between study arms. There was also significant heterogeneity in major bleeding which required further exploration by sub-group analyses. The only evidence of treatment interaction was with heparin dose. Bivalirudin was only associated with a reduction in major bleeding when compared against high-dose heparin.

Our analysis confirmed the findings of Cassese and others who also concluded that bivalirudin was associated with an increase in stent thrombosis and a reduction in major bleeding compared with heparin [52]. However, that analysis included the entire EUROMAX cohort in which the control arm mostly received heparin plus a routine glycoprotein IIb/IIIa inhibitor [53]. In contrast, we used the pre-specified cohort in which the control arm received heparin plus a bailout glycoprotein IIb/IIIa inhibitor [34]. Compared with that study, our analysis includes 5 additional trials. Bertrand and colleagues concluded that bivalirudin was associated with similar ischemic events and a reduction in major bleeding compared with heparin; however, the majority of their database consisted of observational studies, which are also prone to bias [54]. A strength of our analysis is that it removed the confounding effects of glycoprotein IIb/IIIa inhibitors. In doing so, we revealed that bivalirudin may still be associated with a modest reduction in major bleeding, which was most evident when compared against heparin ≥ 100 units/kg. Therefore, in catheterization laboratories that use heparin doses ≤ 75 units/kg, the use of bivalirudin may not result in a notable reduction in major bleeding.

It is uncertain why bivalirudin was associated with an increased hazard of stent thrombosis when the frequency of ADP antagonists and glycoprotein IIb/IIIa inhibitors was similar.

Fig 3. Summary plot of major bleeding for bivalirudin arm versus heparin according to doses ≤ 75 units/kg versus doses ≥ 100 units/kg. The relative size of the data markers indicates the weight of the sample size from each study. CI = confidence interval; OR = odds ratio.

doi:10.1371/journal.pone.0127832.g003
between study groups. It is possible that this finding was not an effect of the drug, but rather a process of its use. For example, with unfractionated heparin, activated clotting time (ACT) values are routinely checked and the drug is titrated to achieve therapeutic effect. With bivalirudin, it is generally not recommended to follow ACT values. However, this blood value provides a safety check to ensure that the drug has been infused through a patent peripheral intravenous line and is exerting a systemic effect. In both the Novel Approaches in Preventing or Limiting Event III (NAPLES III) and the How Effective are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention (HEAT-PPCI) trials, which comprised approximately 14% of the study weight of this analysis, ACT values were checked in both study groups [31,33]. Had a peripheral intravenous line become infiltrated in one of these trials, it would have been discovered and corrected before an adverse event could occur. In distinction, a trial in which ACT values were not checked in the bivalirudin arm was the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial [13]. This trial also allowed for upstream anticoagulation, which could have resulted in bias by allowing for supra-therapeutic anti-coagulation in the bivalirudin arm. This formed the basis for one of our sensitivity analyses. We found the hazard of stent thrombosis persisted after excluding trials that allowed for upstream anticoagulation. Accordingly, it is unlikely that lack of uniform ACT evaluation among bivalirudin treated patients could explain our study findings.

Another potential explanation for the increased hazard of stent thrombosis with bivalirudin is that unfractionated heparin has been shown to be a more potent inhibitor of the thrombin-inducible platelet protease-activated receptor (PAR)-1 than bivalirudin. This might result in more potent anti-platelet activity and hence less stent thrombosis with unfractionated heparin [55].

In the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial, the risk of stent thrombosis was higher with bivalirudin versus unfractionated heparin plus glycoprotein IIb/IIIa inhibitor [9]. The investigators hypothesized this could have been due to the rapid offset of action of bivalirudin prior to
maximal anti-platelet effect from ADP antagonists. This influenced the European Ambulance Acute Coronary Syndrome Angiography (EUROMAX) trial design so that bivalirudin was continued at a reduced dose for several hours after the procedure [53]. In addition, most of the patients were treated with either ticagrelor or prasugrel. Despite this design change, there was still an excess hazard of stent thrombosis among bivalirudin treated patients [34,53].

Our study has some limitations. We included trials that compared bivalirudin plus a routine glycoprotein IIb/IIIa inhibitor versus heparin plus a routine glycoprotein IIb/IIIa inhibitor. Although bivalirudin is not routinely used with a glycoprotein IIb/IIIa inhibitor in clinical practice, this randomization was consistent with our study design which eliminated bias from unequal use of glycoprotein IIb/IIIa inhibitors. We included trials that allowed for upstream non-study anti-coagulation (ie, fondaparinux in SWITCH III and heparin in ACUITY). This is also not consistent with clinical practice and may result in bias since ACT values are more routinely measured with heparin; however, our results were materially unchanged in a sensitivity analysis that excluded these trials. In the ARNO trial, all heparin treated patients received protamine following the procedure. This could have caused bias in favor of bivalirudin; however, the findings remained the same after this trial (and MATRIX, EUROMAX and SWITCH III) were excluded in a sensitivity analysis that excluded studies with a modest difference in glycoprotein IIb/IIIa inhibitor usage between study arms. We included the entire spectrum of PCI patients (ie, elective and acute coronary syndromes); however, we considered this approach valid since bivalirudin has been studied and is approved for all of these indications. Lastly, some of the included studies had small sample size, although we included all available studies to avoid any risk of publication bias [36].

Conclusion

In conclusion, among a broad spectrum of patients undergoing PCI, bivalirudin compared with heparin was associated with an increased hazard for stent thrombosis. This was mostly due to acute stent thrombosis and during acute coronary syndromes. Bivalirudin may be associated with a reduction in major bleeding when compared with unfractionated heparin ≥ 100 units/kg.

Supporting Information

S1 Table. Definition of major bleeding, major adverse cardiac events, and net adverse clinical events among the individual trials. *REPLACE-2 criteria: massive bleeding or life-threatening hemorrhage, such as intracranial hemorrhage, retroperitoneal bleeding, clinically overt bleeding that resulted in a decrease in hemoglobin >3 gram% or transfusion of 2 or more units of packed red blood cells or whole blood. †TIMI criteria: intracranial bleeding or clinically overt bleeding associated with a decrease in hemoglobin >5 g/dl. CABG = coronary artery bypass graft surgery; MI = myocardial infarction; NR = not reported.

S2 Table. Assessment of study quality components. *The clinical events committee was blinded to the treatment allocation. Data are formatted as bivalirudin arm/ unfractionated heparin arm. MI = myocardial infarction; NR = not reported.

S1 Fig. PRISMA checklist. Reports the location in the paper of each item as outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Acknowledgments

We would like to thank Dr. Jonathan J Shuster for his guidance with statistical methods.

Author Contributions

Conceived and designed the experiments: AAB. Performed the experiments: AAB IYE AM MPJ. Analyzed the data: AAB IYE AM MPJ TH. Contributed reagents/materials/analysis tools: TH. Wrote the paper: AAB IYE AM MPJ TH.

References

1. Winchester DE, Wen X, Brearley WD, Park KE, Anderson RD, Bavry AA. Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines. J Am Coll Cardiol. 2011; 57: 1190–1199. doi: 10.1016/j.jacc.2010.10.030 PMID: 21371635
2. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003; 289: 853–863. PMID: 12588269
3. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011; 58: e44–122. doi: 10.1016/j.jacc.2011.08.007 PMID: 22070834
4. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. Guidelines on myocardial revascularization. Eur Heart J. 2010; 31: 2501–2555. doi: 10.1093/eurheartj/ehq277 PMID: 20802248
5. Cavender DA, Sabatine MS. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. Lancet. 2014; 384: 599–606. doi: 10.1016/S0140-6736(14)61216-2 PMID: 25131979
6. Nairooz R, Sardar P, Amin H, Swaminathan RV, Kim LK, Chatterjee S, et al. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2014; 114: 250–259. doi: 10.1016/j.amjcard.2014.04.033 PMID: 24890986
7. Gibson CM, Morrow DA, Murphy SA, Palabrica TM, Jennings LK, Stone PH, et al. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. J Am Coll Cardiol. 2006; 47: 2364–2373. PMID: 16781360
8. Kastrati A, Neumann FJ, Schulz S, Massberg S, Byrne RA, Ferenc M, et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med. 2011; 365: 1980–1989. doi: 10.1056/NEJMoa1109596 PMID: 22077909
9. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008; 358: 2218–2230. doi: 10.1056/NEJMoia0708191 PMID: 18499566
10. Lincoff AM, Kleiman NS, Kottke-Marchant K, Maierson ES, Maresh K, Wolski KE, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J. 2002; 143: 847–853. PMID: 12040347
11. Tavano D, Visconti G, D’Andrea D, Focaccio A, Golia B, Librera M, et al. Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention. Am J Cardiol. 2009; 104: 1222–1228. doi: 10.1016/j.amjcard.2009.06.033 PMID: 19840566
12. Schulz S, Richardt G, Lauwitz KL, Morath T, Neudecker J, Hoppmann P, et al. Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2014; 35: 2285–2294. doi: 10.1093/eurheartj/ehu182 PMID: 24816809
13. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006; 355: 2203–2216. PMID: 17124018
14. Antman EM, McCabe CH, Braunwald E. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction. Am Heart J. 2002; 143: 229–234. PMID: 11835024
29. Valgimigli M; for the MATRIX group. Bivalirudin infusion compared to unfractionated heparin in patients
Han Y, Guo J, Zheng Y, Zang H, Su X, Wang Y, et al. Bivalirudin vs. heparin with or without tirofiban
30. 15.
16.
Theroux P, Perez-Villa F, Waters D, Lesperance J, Shabani F, Bonan R. Randomized double-blind
Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M, et al. Use of a direct antithrombin, hiru-
17.
18.
White HD, Ohman EM, Lincoff AM, Bertrand ME, Colombo A, McLaurin BT, et al. Safety and efficacy of
Lev EI, Patel R, Karim A, Kleiman A, Badimon JJ, Kleiman NS. Anti-thrombotic effect of bivalirudin com-
20.
22.
Kleiman NS, Klem J, Fernandes LS, Rubin H, Challa S, Solomon S, et al. Pharmacodynamic profile of
Anand SX, Kim MC, Kamran M, Sharma SK, Kini AS, Fareed J, et al. Comparison of platelet function
21.
23.
Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angio-
30.
[Image 36x741 to 143x765]
31. Briguori C, Visconti G, Focaccio A, Donahue M, Golia B, Selvetella L, et al. Novel approaches for preventing or limiting events (NAPLES) III Trial. Randomised comparison of bivalirudin versus unfractionated heparin in patients at increased risk of bleeding undergoing transfemoral elective coronary stenting. JACC Cardiovasc Intervent. 2015; 8: 414–423.

32. Feldman A, Suleiman K, Bushari L, Yahalom M, Rozner E, Freedberg NA, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients at high risk for bleeding. Int J Angiol. 2014; 23: 227–232. doi: 10.1055/s-0034-1372244 PMID: 25484553

33. Shahzad A, Kemp I, Mars C, Wilson K, Roome C, Cooper R, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet. 2014; 384: 1849–1858. doi: 10.1016/S0140-6736(14)60924-7 PMID: 25002178

34. Zeymer U, van ’t Hof A, Adgey J, Nibbe L, Clemmensen P, Cavallini C, et al. Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial. Eur Heart J. 2014; 35: 2460–2467. doi: 10.1093/eurheartj/ehu214 PMID: 24849104

35. Xiang DC, Gu XL, Song YM, Huang WJ, Tang LQ, Yin YH, et al. Evaluation on the efficacy and safety of domestic bivalirudin during percutaneous coronary intervention. Chin Med J (Engl). 2013; 126: 3064–3068. PMID: 23981613

36. Wakeman R, Bertrand O, Driesman M, Gruberg L, Rossi J, Mehta S, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III). J Interv Cardiol. 2013; 26: 107–113. doi: 10.1111/joc.12005 PMID: 23240743

37. Patti G, Pascrei V, D’Antonio L, D’Ambrosio A, Macri M, Dicuonzo G, et al. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study). Am J Cardiol. 2012; 110: 478–484. doi: 10.1016/j.amjcard.2012.04.017 PMID: 22583760

38. Parodi G, Migliorini A, Valenti R, Bellandi L, Signorini U, Moschi G, et al. Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] trial). Am J Cardiol. 2010; 105: 1053–1059. doi: 10.1016/j.amjcard.2009.12.001 PMID: 20381652

39. Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Büttner HJ, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med. 2008; 359: 688–696. doi: 10.1056/NEJMoa0802944 PMID: 18703471

40. Deshpande NV, Pratiti R, Admane P, Mukherjee D, Mardikar HM. Safety and efficacy of bivalirudin with glycoprotein IIb/IIIa for high-risk percutaneous coronary intervention. Indian Heart J. 2012; 64: 444–448. doi: 10.1016/j.ijhj.2012.07.022 PMID: 23102380

41. Moliterno DJ; TENACITY Steering Committee and Investigators. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial. Catheter Cardiovasc Interv. 2011; 77: 1001–1009. doi: 10.1002/ccd.22876 PMID: 21598351

42. Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet. 2007; 369: 907–919. PMID: 17368152

43. Lincoff AM, Bittl JA, Kleiman NS, Sarembock IJ, Jackman JD, Mehta S, et al.; REPLACE-1 Investigators. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol. 2004; 93: 1092–1096. PMID: 15110198

44. Mauri L, Hsieh WH, Massaro JM, Ho KK, D’Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007; 356: 1020–1029. PMID: 17299621

45. Higgins JP, Deeks JJ, Altman DG. 16.9.5 Validity of methods of meta-analysis for rare events. In: Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration; 2011. Available: http://hiv.cochrane.org/sites/hiv.cochrane.org/files/uploads/Ch16_Specialstatistics.pdf. Accessed 29 July 2014.

46. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985; 27: 335–371. PMID: 2858114
47. Shuster JJ, Guo JD, Skyler JS. Meta-analysis of safety for low event-rate binomial trials. Res Synth Methods. 2012; 3. doi: 10.1002/jrsm.1039

48. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327: 557–560. PMID: 12958120

49. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006; 25: 3443–3457. PMID: 16345038

50. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339: b2535. doi: 10.1136/bmj.b2535 PMID: 19622551

51. Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ. 2001; 323: 42–46. PMID: 11440947

52. Cassese S, Byrne RA, Laugwitz KL, Schunkert H, Berger PB, Kastrati A. Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials. EuroIntervention. 2014 Aug 8. pii: 20140729e. doi: 10.4244/EIJY14M08_01 PMID: 25102830

53. Steg PG, van ’t Hof A, Hamm CW, Clemmensen P, Lapostolle F, Coste P, et al.; EUROMAX Investigators. Bivalirudin started during emergency transport for primary PCI. N Engl J Med. 2013; 369: 2207–2217. doi: 10.1056/NEJMoa1311096 PMID: 24171499

54. Bertrand OF, Jolly SS, Rao SV, Patel T, Belle L, Bernat I, et al. Meta-analysis comparing bivalirudin versus heparin monotherapy on ischemic and bleeding outcomes after percutaneous coronary intervention. Am J Cardiol. 2012; 110: 599–606. doi: 10.1016/j.amjcard.2012.03.051 PMID: 22591669

55. Eslam RB, Reiter N, Kaider A, Eichinger S, Lang IM, Panzer S. Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin and bivalirudin. Eur Heart J. 2009; 30: 1831–1836. doi: 10.1093/eurheartj/ehp186 PMID: 19468011

56. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000; 53: 1119–1129. PMID: 11106885